Pentadecapeptide BPC (Oral)

Overview

Oral BPC-157 refers to stabilized oral preparations of the pentadecapeptide Body Protection Compound-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), most commonly the arginate salt (sometimes acetate or enteric-coated capsules), intended to survive gastric transit and improve absorption versus the unformulated peptide. This entry covers the salt/stabilized formulations specifically; generic BPC-157 capsules without a salt-form claim are classified under the base BPC-157 entry.

Mechanism of Action

The peptide portion shares the same proposed mechanism as injectable BPC-157 — NO-system modulation, VEGFR2 activation, FAK–paxillin signaling, and upregulation of growth factors involved in tissue repair — plus direct gastrointestinal mucosal contact for local effects on the GI lining. The arginine counter-ion is claimed to improve aqueous stability and resistance to acid-mediated degradation relative to the acetate form; comparative bioavailability claims circulating in marketing material come from vendor/patent sources rather than peer-reviewed human pharmacokinetic studies.

Research Summary

Sikiric and colleagues have shown that peroral BPC-157 (given in drinking water in rats) produces both local GI effects (IBD, gastric ulcer, NSAID damage, short bowel syndrome, fistulas) and systemic effects (tendon, liver, CNS models) at microgram- and nanogram-per-kilogram doses. The peptide is reported to be stable in human gastric juice for more than 24 hours. No human clinical trials of arginate, acetate, or enteric-coated oral BPC-157 have been published, and there are no peer-reviewed head-to-head pharmacokinetic comparisons between salt forms in humans.

Dosing Information

Reported Side Effects

• Mild nausea
• Gastrointestinal discomfort
• Headache
• Dizziness

Research References

• Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review of peroral dosing and gastric juice stability) (2011)
• Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats (peroral administration in drinking water) (2009)
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (gastric juice stability >24 h) (2021)